Idorsia IDIA

SWX: IDIA | ISIN: CH0363463438   12:25
2,274 CHF (-3,32%)
(-3,32%)   12:25

14 mei 2024 · Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call · Persbericht

6 mei 2024 · Bondholders approve amended terms of the 2024 convertible bonds · Persbericht

1 mei 2024 · Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond · Persbericht

26 april 2024 · JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension · Persbericht

23 april 2024 · Idorsia publishes an invitation to a bondholder meeting · Persbericht

17 april 2024 · Idorsia publishes a Financial Status required for an upcoming bondholder meeting · Persbericht

11 april 2024 · Idorsia takes steps to address short-term liquidity needs · Persbericht

22 maart 2024 · Idorsia thanks Guy Braunstein for his years of service as he retires · Persbericht

20 maart 2024 · US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives · Persbericht

18 maart 2024 · Idorsia and Viatris successfully close the transaction for the global research and development collaboration · Persbericht

28 februari 2024 · Idorsia and Viatris enter into a significant global research and development collaboration · Persbericht

10 januari 2024 · Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation · Persbericht

3 november 2023 · New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023 · Persbericht

24 oktober 2023 · Idorsia announces financial results for the first nine months of 2023 – adapting the company to create sustainable value · Persbericht

23 oktober 2023 · Idorsia is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023 · Persbericht

17 oktober 2023 · Invitation to Idorsia's Nine-Month 2023 Financial Reporting webcast and conference call · Persbericht

6 september 2023 · Idorsia reacquires the world-wide rights to aprocitentan · Persbericht

25 juli 2023 · Idorsia announces financial results for the first half 2023 – adapting the company to create sustainable value · Persbericht

21 juli 2023 · Idorsia announces a cost reduction initiative to be implemented by the end of 2023 · Persbericht

20 juli 2023 · Idorsia sells its Asia Pacific (ex-China) operations – including select license rights to products – to Sosei Heptares for a total consideration of CHF 400 million · Persbericht

Mijn selecties